TG Therapeutics Q3 net loss $85.6M; UKONIQ revenue $2.0M; ublituximab BLA for RMS submitted

TG THERAPEUTICS, INC.

2022-Q3 EPS reported -$1.93 revenue$4,368,000

Net loss $85.6M Q3, $254.8M nine months; ex-stock comp net loss $71.6M and $207.8M.
Product revenue $2.0M Q3, $4.3M YTD from UKONIQ launch (approx 7 months post-approval).
BLA for ublituximab submitted for RMS; PDUFA date for U2 in CLL set for March 25, 2022.
Cash $381.4M as of Sept 30; expected to fund operations into 2023.
R&D $52.0M and SG&A $34.9M in Q3; costs increased due to regulatory submissions and launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.